GLP-1 & Incretin Science

PYY(3-36): The Satiety Signal Scaled to the Meal

UKPWritten and published by UK Peptides4 min readUpdated 2 cited sources

The short answer

Peptide YY is a gut hormone released after a meal in proportion to its calorie content. Its active fragment PYY(3-36) is a Y2 receptor agonist that reduces food intake, and in one human study reduced 24-hour intake by 33% at ordinary postprandial concentrations.

Key facts

Active fragment
PYY(3-36)
Receptor
NPY Y2 receptor
Where the receptor sits
Presynaptically on NPY neurons of the arcuate nucleus
Release stimulus
Postprandial, proportional to meal calorie content
Enzyme producing the active form
DPP-4
Human result
33% reduction in food intake over 24 hours on infusion
Genetic control
No anorectic effect in Y2r-null mice
Key paper
Batterham RL et al., Nature 2002 (PMID 12167864)

The hormone that measures the meal

Most appetite signals report a state: how much fat is stored, how long since the last meal. PYY reports an event. It is released from the gastrointestinal tract after eating, and Batterham and colleagues describe that release as being in proportion to the calorie content of the meal. That makes it a quantitative postprandial signal rather than a binary one, which is a meaningfully different kind of information for the brain to receive and a reason the hormone attracted so much interest as a target.

The DPP-4 twist

PYY is secreted as PYY(1-36) and cleaved to PYY(3-36) by dipeptidyl peptidase-4, the same enzyme that inactivates GLP-1 within minutes of its release. The two truncations do opposite things. Cleaving GLP-1 destroys it. Cleaving PYY converts it from a form with broad NPY-receptor activity into one that is selective for the Y2 receptor, which is the receptor through which the anorectic effect runs. The same enzymatic step is a termination signal for one gut hormone and an activation step for another. Anyone who has read that DPP-4 simply degrades gut peptides has half the picture.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

How the circuit works

The Y2 receptor is described as a putative inhibitory presynaptic receptor and is highly expressed on the NPY neurons of the arcuate nucleus, a region accessible to peripheral hormones. NPY neurons drive feeding. POMC neurons, which sit adjacent, suppress it, and the two populations inhibit each other. Batterham and colleagues showed that PYY(3-36) inhibits the electrical activity of NPY nerve terminals, which releases the adjacent POMC neurons from inhibition and activates them. So the hormone reduces feeding twice over from a single action: it silences the drive and, by silencing it, releases the brake. Peripheral administration increased c-Fos immunoreactivity in the arcuate nucleus and decreased hypothalamic Npy messenger RNA, and injecting PYY(3-36) directly into the arcuate nucleus inhibited food intake on its own.

The genetic control, and why it matters

PYY(3-36) inhibited food intake in mice, but not in Y2r-null mice. That is the experiment that converts an observed effect into an identified route. Without it, a hormone that reduces feeding could be doing so through any of a dozen mechanisms including simple malaise. With it, the anorectic effect is shown to require the specific receptor the model proposes. This is the same logical structure as the PepT1 knockout in the KPV literature and the GDF15-null mice in the metformin work, and it is the single most informative experiment a mechanistic paper can run.

The human number, and its limits

In humans, infusion of PYY(3-36) at concentrations matching those seen normally after a meal significantly decreased appetite and reduced food intake by 33% over 24 hours. That is a large effect and it was achieved without pharmacological concentrations; the design deliberately kept the exposure physiological. It is also an acute infusion study measuring intake over one day in a laboratory setting, which is a long way from sustained weight change. Acute intake studies and chronic weight trials disagree routinely, and a compound that reduces one meal's intake by a third may do nothing measurable to body weight over a year.

Why PYY has not become a drug

It has been pursued repeatedly and has not produced a licensed weight-management medicine. The reasons illustrate a general problem with this class of target. Native PYY(3-36) has a short circulating life, so it needs engineering to be dosed practically. Nausea has been dose-limiting in clinical work, which is the recurring tax on hindbrain and hypothalamic appetite signals. And the acute effect on a single day's intake has repeatedly failed to translate into the sustained divergence in body weight that a weight-management indication requires. PYY analogues remain in development, including in combination with incretins, on the reasoning that partial engagement of several pathways may achieve more than full engagement of one.

Frequently asked questions

Is PYY the same as NPY?

No, though they are related and the names invite confusion. NPY is a central neuropeptide that stimulates feeding. PYY is a gut hormone whose active fragment suppresses it, acting at a receptor expressed on NPY neurons. They belong to the same peptide family and do opposite things.

Does eating more release more PYY?

Release is described as proportional to the calorie content of the meal, so in that specific sense yes. That proportionality is what makes it a signal about the meal rather than about the fed state generally.

Why is a 33% reduction in intake not enough for a drug?

Because it was measured over 24 hours during an infusion. Body weight is determined over months, and compensatory responses (increased hunger, reduced energy expenditure) accumulate over that timescale and are invisible in a one-day study.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.